MCRB Key Statistics, Chart & Performance
The current stock price of MCRB is 13.63 USD. In the past month the price decreased by -12.35%. In the past year, price decreased by -12.85%.
MCRB Technical Analysis
MCRB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MCRB. MCRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MCRB Financial Highlights
Over the last trailing twelve months MCRB reported a non-GAAP Earnings per Share(EPS) of -6.29. The EPS increased by 73.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1536.75% | ||
| ROA | 3.76% | ||
| ROE | 12.34% | ||
| Debt/Equity | 0 |
MCRB Forecast & Estimates
9 analysts have analysed MCRB and the average price target is 21.42 USD. This implies a price increase of 57.15% is expected in the next year compared to the current price of 13.63.
MCRB Ownership
MCRB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.95 | 383.716B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.37 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.68 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.14 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.01 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MCRB
Company Profile
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Company Info
SERES THERAPEUTICS INC
101 Cambridge Park Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Eric D. Shaff
Employees: 103
Phone: 16179459626
SERES THERAPEUTICS INC / MCRB FAQ
What does SERES THERAPEUTICS INC do?
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
What is the current price of MCRB stock?
The current stock price of MCRB is 13.63 USD. The price decreased by -11.49% in the last trading session.
Does MCRB stock pay dividends?
MCRB does not pay a dividend.
How is the ChartMill rating for SERES THERAPEUTICS INC?
MCRB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of SERES THERAPEUTICS INC (MCRB)?
SERES THERAPEUTICS INC (MCRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.29).
Can you provide the number of employees for SERES THERAPEUTICS INC?
SERES THERAPEUTICS INC (MCRB) currently has 103 employees.
Who owns SERES THERAPEUTICS INC?
You can find the ownership structure of SERES THERAPEUTICS INC (MCRB) on the Ownership tab.